Y-Biologics KRX:338840KOSDAQ

와이바이오로직스 · Korean news coverage and regulatory filings, organized.

Articles, 24h2
Articles, 7 days2
DART filings, 7 days2
Articles tracked26since Sep 11

In Q3 2026, Y-Biologics reported revenue of ₩292m, down 67.3% year on year, and an operating loss of ₩5.1bn. Y-Biologics (와이바이오로직스) appeared in 2 Korean news articles and 2 DART filings over the past seven days. Coverage peaked on Nov 5 with 6 articles. The most common catalyst was contracts & orders (3). It was most often mentioned alongside 글로벌테크놀로지, Curocell and GI Innovation.

Filing signals Insider buying 4 quarters of losses Screener

Y-Biologics at a glance from DART filings

Results trend
Operating loss in each of the last 4 quarters; Q3 2026 operating loss of ₩5.1bn a loss again after the previous quarter.
Ownership changes
11 5%-holder and insider ownership reports in the past 120 days (9 increases, 2 decreases).

Figures the company filed on DART, grouped by ATS View. Not a buy or sell call; see the cards below and the DART originals.

Y-Biologics today: up or down?

No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.

Upcoming dates as filed

  • Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026

Dates Y-Biologics stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.

Y-Biologics quarterly results separate, KRW

QuarterRevenueYoYOperating profitNet income
Q3 2026₩292m-67.3%−₩5.1bn−₩5.8bn
Q2 2026₩1.5bn+32.8%−₩3.8bn
margin −244.9%
−₩7.8bn
Q1 2026₩282m-30.8%−₩3.9bn−₩4.3bn
Q4 2025 derived₩449m-60.9%−₩3.0bn−₩35.1bn
Q3 2025₩892m-72.5%−₩2.5bn
margin −283.5%
−₩2.7bn
Q2 2025₩1.2bn+402.0%−₩1.5bn
margin −128.4%
−₩2.3bn
Q1 2025₩407m-64.4%−₩2.3bn−₩1.9bn
Q4 2024 derived₩1.1bn+86.2%−₩2.4bn
margin −205.9%
−₩1.8bn

Y-Biologics ranks #2211 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Y-Biologics top stories 2 weeks, by number of outlets

  1. 1
    Y Biologics pursues global technology transfer led by Multiapykine
    1 outlets · 1 articlesFirst report Nov 5 08:27 메디파나뉴스Licensing deal글로벌테크놀로지
  2. 2
    WiBio Therapeutics seeks global technology transfer opportunities with latest immune-oncology data
    1 outlets · 1 articlesFirst report Nov 5 09:12 메디컬투데이Licensing deal글로벌테크놀로지
  3. 3
    Y Biologics pursues global technology transfer of 'next-generation Keytruda' AR170, AR166
    1 outlets · 1 articlesFirst report Nov 16 11:23 리드경제Licensing deal글로벌테크놀로지
  4. 4
  5. 5
    Y Biologics participates in Germany's BioEurope 2026
    1 outlets · 1 articlesFirst report Nov 5 09:04 뉴스핌
  6. 6

Latest Y-Biologics news Korean headlines